Open AccessLong-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
Author(s) -
D.A. Margolis,
J. Gonzalez-Garcia,
H.-J. Stellbrink,
Joe Eron,
Y. Yazdanpanah,
D. Podzamczer,
T. Lutz,
J.B. Angel,
G.J. Richmond,
B. Clotet,
F. Gutierrez,
L. Sloan,
Mary Clair,
M. Murray,
S.L. Ford,
J. Mrus,
Pragat Patel,
H. Crauwels,
S.K. Griffith,
K.C. Sutton,
D. Dorey,
K.Y. Smith,
P.E. Williams,
W.R. Spreen
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/h9d5-zm95
Subject(s) - rilpivirine , medicine , human immunodeficiency virus (hiv) , open label , randomized controlled trial , virology , antiretroviral therapy , viral load